Table of Contents
Historical Data, Premium Insights, Market Dynamic, Analysis and Projection, By Product, Analysis and Projection, By Application, Analysis and Projection, By End-Use, Analysis and Projection, By Regional Analysis, Competitive Landscape, Company Profiles, Market Revenue, Sale & Price Analysis
Related Topics
Chronic Kidney Disease (CKD) Drug Market Size Chronic Kidney Disease (CKD) Nutritional Supplements Market Size Cardiovascular Diagnostic and Monitoring Market Size Heat Recovery Ventilator Market SizeGlobal Chronic Kidney Disease Market Size to Exceed USD 66.65 Billion by 2033
According to a research report published by Spherical Insights & Consulting, The Global Chronic Kidney Disease Market Size is Expected to Grow from USD 38.30 Billion in 2023 to USD 66.65 Billion by 2033, at a CAGR of 5.70% during the forecast period 2023-2033.
Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Chronic Kidney Disease Market Size, Share, and COVID-19 Impact Analysis, By Diagnosis (Blood Test, Urine Test, Imaging Test, and Kidney Biopsy), By Treatment (Drugs, Dialysis, and Kidney Transplant), By End-User (Hospital & Clinics and Diagnostic Centers), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
The chronic kidney disease (CKD) market is the global market dedicated to the diagnosis, management, and treatment of chronic kidney disease, a chronic condition that permanently damages kidney function. The market encompasses pharmaceutical medication, diagnostic equipment, dialysis equipment, kidney transplant products, and nutritional supplements aimed at slowing disease progression, symptom management, and enhancing patient outcomes. Furthermore, the global chronic kidney disease (CKD) market is fuelled by the growing incidence of CKD, rising geriatric population, and rising awareness of early treatment and diagnosis. Progress in drug development, government policies, better healthcare infrastructure, and increasing use of dialysis and kidney transplants accelerate market growth further. The rising incidence of diabetes and hypertension also drives demand for CKD management. However, the high treatment costs, limited awareness, stringent regulatory approvals, lack of early diagnosis, reimbursement challenges, and restricted access to advanced healthcare in developing regions are key restraints for the growth of the market.
The blood test segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.
On the basis of the diagnosis, the global chronic kidney disease market is divided into blood test, urine test, imaging test, and kidney biopsy. Among these, the blood test segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth is attributed to its effectiveness in early CKD detection, widespread use in monitoring kidney function, and increasing awareness of routine screenings. Advancements in diagnostic technologies, growing CKD prevalence, and rising demand for cost-effective, rapid, and accurate diagnostic solutions further drive its significant CAGR during the forecast period.
The drugs segment accounted for the largest share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period.
On the basis of treatment, the global chronic kidney disease market is divided into drugs, dialysis, and kidney transplant. Among these, the drugs segment accounted for the largest share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period. The segmental growth is attributed to the rising prevalence of CKD, increasing adoption of medications for disease management, and ongoing advancements in drug development. Growing awareness, improved access to pharmaceutical treatments, and the expanding availability of effective therapies further drive the segment’s remarkable CAGR during the forecast period.
The hospital & clinics segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period.
On the basis of the end-user, the global chronic kidney disease market is divided into hospital & clinics, and diagnostic centers. Among these, the hospital & clinics segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period. The segmental growth is propagated by the high patient influx for CKD diagnosis and treatment, the availability of advanced medical facilities, and the presence of skilled healthcare professionals. Increasing healthcare investments, improved access to specialized treatments, and rising awareness about CKD management further drive its substantial CAGR over the forecast period.
North America is projected to hold the largest share of the global chronic kidney disease market over the forecast period.
North America is projected to hold the largest share of the global chronic kidney disease market over the forecast period. The regional growth is attributed to the high prevalence of CKD, advanced healthcare infrastructure, and the strong presence of key pharmaceutical and diagnostic companies. Favorable reimbursement policies, increasing healthcare expenditure, rising awareness about early disease detection, and continuous advancements in treatment options further drive the region’s significant market share.
Asia Pacific is expected to grow at the fastest CAGR growth of the global chronic kidney disease market during the forecast period. The regional growth is attributed to the rising prevalence of chronic kidney disease, an aging population, and increasing healthcare investments. Expanding access to advanced treatments, improving healthcare infrastructure, and growing awareness about CKD management contribute to the region’s rapid market expansion during the forecast period.
Company Profiling
Major vendors in the global chronic kidney disease market are Abbott, Siemens, Beckman Coulter, F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc, Nova Biomedical, ARKRAY, AstraZeneca, GlaxoSmithKline Plc, Bayer AG, and others.
Key Target Audience
Recent Development
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global chronic kidney disease market based on the below-mentioned segments:
Global Chronic Kidney Disease Market, By Diagnosis
Global Chronic Kidney Disease Market, By Treatment
Global Chronic Kidney Disease Market, By End-User
Global Chronic Kidney Disease Market, By Regional
May 2025 - The Global Chronic Kidney Disease Treatment Market Size is Expected to Grow from USD 33.20 Billion in 2023 to USD 47.99 Billion by 2033, at a CAGR of 3.75% during the forecast period 2023-2033
May 2025 - The Global Chronic Kidney Disease (CKD) Drug Market Size is Expected to Grow from USD 14.2 Billion in 2023 to USD 20.80 Billion by 2033, at a CAGR of 3.89% during the forecast period 2023-2033
May 2025 - The Global Chronic Kidney Disease (CKD) Nutritional Supplements Market Size is Expected to Grow from USD 3.56 Billion in 2023 to USD 5.20 Billion by 2033, at a CAGR of 3.86% during the forecast period 2023-2033
We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.
+1 303 800 4326 +91 9561448932 emailsales@sphericalinsights.com
